Navigation Links
Improved Pharma to Speak at 69th Annual Meeting of the American Crystallographic Association
Date:7/19/2019

Improved Pharma LLC announces the upcoming presentation of “Continuity of Solids between Amorphous and Crystalline States – Insights from Synchrotron X-ray Pair Distribution (SXPDF) Studies”. The authors are Stephen R. Byrn and Pamela A. Smith of Improved Pharma, along with Chris Benmore of Argonne National Laboratory and Gabriel de Araujo of the University of Sao Paulo.

One of Improved Pharma’s key areas of research involves understanding the interactions present in amorphous drugs and drug:polymer dispersions. As pioneers in this area, they have worked with leading researchers to hone the experimental approach and also offer this service to their clients in the pharmaceutical industry.

To fully understand the structure of amorphous materials, Synchrotron X-ray Pair Distribution Function (SXPDF) is a powerful analytical tool. To stabilize an amorphous drug, one common approach is to formulate it as a drug:polymer dispersion. If the correct polymer is used at the correct loading, then intermolecular interactions between drug molecules are removed. Stated another way, domains of more than one drug molecule are not present. If the drug molecules are not in close contact with each other, then crystallization is inhibited and stability of the formulation increases. SXPDF allows one to detect and measure these interactions. For example, for pure amorphous preparations of lapatinib, SXPDF shows nearest neighbor contacts out to the 5th order. For compositions of lapatinib and the cellulosic polymer HPMC, only nearest neighbor contacts of the lapatinib molecules are present. For compositions of lapatinib and HPMCP (1:3) no nearest neighbor contacts of the lapatinib molecules are present indicating the lack of lapatinib domains. As expected, this last composition was the most stable indicating a correlation between the existence of domains and the tendency to crystallize.

In this presentation, Dr. Byrn will discuss an overview of the current state of research and present some recent work conducted with our colleagues at Argonne National Laboratory and the University of Sao Paulo. Calcium salts that form liquid crystals will also be discussed.

About Improved Pharma
Improved Pharma is a research and information company dedicated to improving pharmaceutical methods, formulations, and processes. Dr. Stephen Byrn and Sarah Byrn founded the company in 2006 after the successful acquisition of their first company, SSCI. Dr. Pamela Smith joined the company in 2018 after an 18-year tenure with SSCI. Improved Pharma offers services such as analytical testing, synchrotron-based formulation design, and expert consulting aiding the development and defense of intellectual property matters.

For more information about the techniques discussed in this article or about Improved Pharma’s services, please contact us at 1-765-463-9951 or info@improvedpharma.com.

Read the full story at https://www.prweb.com/releases/improved_pharma_to_speak_at_69th_annual_meeting_of_the_american_crystallographic_association/prweb16448783.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Improved Pharma Publishes Review Article in AAPS PharmSciTech
2. Abcam Collaborates with Visikol to Develop New Tools for Improved Tissue Clearing and 3D Imaging
3. Improved mouse model will accelerate research on potential Ebola vaccines, treatments
4. Improved electricity access has little impact on climate change
5. S-equol supplements associated with improved measures of reproductive health in postmenopausal women
6. Federal food program puts food on the table, but dietary quality could be improved
7. Plant variants point the way to improved biofuel production
8. Samtools CRAMS in support for improved compression formats
9. Developing an improved liposuction technique that melts fat
10. University of Toronto biologists pave the way for improved epilepsy treatments
11. New meta-analysis builds on the power of whey protein for improved body composition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2019)... , ... October 07, 2019 , ... The future of ... the genetic level, resulting in people living longer, healthier lives. But it will be ... earth. , Leroy E. Hood, MD, PhD, Chief Strategy Officer and Co-Founder of the ...
(Date:10/4/2019)... ... October 03, 2019 , ... Mount Sinai researchers have discovered how the ... one generation to the next. In a study published in Nature Structural & Molecular ... enzyme, leading to cancers and other diseases. , “DNA polymerase delta serves as the ...
(Date:10/3/2019)... ... 2019 , ... Personalized Stem Cells, Inc (“PSC”), a human adipose-derived ... clinical trial for stem cell treatment of knee osteoarthritis . The successful enrollment comes ... subsidiary of VetStem Biopharma. , PSC CEO, Michael Dale, stated, “We are proud that ...
Breaking Biology News(10 mins):
(Date:10/3/2019)... ... October 01, 2019 , ... Today Cereset®, the only proven ... point of its randomized research trial for individuals with persisting symptoms following mild-Traumatic ... of a non-invasive technology which compares tones delivered to a subject’s brain guided ...
(Date:10/3/2019)... ... ... Murrieta Genomics , the launch pad for genomic sequencing startups, will be ... a special Life Science showcase event on October 10th, 2019 from 4 ... Center located at 340 E. Middlefield Road in Mountain View, California. , “Murrieta ...
(Date:10/3/2019)... ... 03, 2019 , ... Yesterday, at the 2019 meeting of Outsourcing in Clinical ... L. Sherley, M.D., Ph.D., discussed important design factors that currently limit the success of ... and suppliers of clinical trials, in his talk Dr. Sherley focused on ...
(Date:9/24/2019)... ... 24, 2019 , ... Drug resistance has been declared as one of the ... becoming one of the most serious concerns. Hong Kong cannot be spared from the ... (CA-MRSA), or a seven-fold of the figure in 2007 – the year the disease ...
Breaking Biology Technology: